Search

Adding elotuzumab to standard treatment for multiple myeloma significantly reduced the risk of disease progression, with benefits sustained at two years

ELOQUENT-2, which evaluated elotuzumab in combination with lenalidomide and dexamethasone, is the first Phase III study to demonstrate the benefit of directly activating the immune system in the treatment of patients with relapsed or refractory multiple myeloma.

Read more

Participation grants & abstract awards

Participation grants
The call for participation grant applications has closed on March 1, 2021 (23:59 CET). Participation grant application has closed

Participation Grants (previously called Travel Grants) provide complimentary registration for the upcoming EHA Virtual Congress.

Read more

Call for interest — new La Cantera event

The call for interest is open until 23:59 on November 30, 2024. Complete the Word application form now

In 2025, EHA will provide funding for a new La Cantera coaching event.

Read more